source
- Phase 3 trial shows Wainua fails to improve outcomes in ATTR-CM, hazard ratio 1.14AstraZeneca and Ionis Pharmaceuticals presented detailed results from the Phase 3 trial of their antisense oligonucleotide Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardi…
- Priovant's Lisraya receives first FDA approval as oral therapy for dermatomyositisThe U.S. Food and Drug Administration has cleared Priovant Therapeutics' daily TYK2/JAK1 inhibitor tablet, marketed under the name Lisraya, for the treatment of dermatomyositis in adults. Lisraya…